Leverage nonclinical development of bispecifics by translational science

Publication date: Available online 27 October 2016 Source:Drug Discovery Today: Technologies Author(s): Andreas Baumann, Stephanie Fischmann, Guenter Blaich, Matthias Friedrich Bispecific antibody constructs (Bispecifics, bsAbs) may have greater functionality compared to established monoclonal antibodies because they bind to 2 different targets or, potentially, to 2 epitopes on the same target (dual targeting). This may result in enhanced binding avidity with preferential binding to cells that express both targets or binding to targets on different cells. However, development of these next-generation biologics, including new formats, creates unique challenges due to their increased complexity. Here we review aspects of bsAbs preclinical development programs that may increase the success rates of bsAbs in clinical development.
Source: Drug Discovery Today: Technologies - Category: Drugs & Pharmacology Source Type: research